There are 1.4B people in the world suffering from neglected diseases such as Dengue, Malaria and Zika. Over the past decades, there has been a shortage of funding and drug development targeting these diseases in comparison to cancer and rare diseases. RebelPharma’s goal is to bridge this gap. 

There are over 1.4B people suffering from neglected diseases (NDs) such as dengue, malaria, zika and others, mostly in the developing world. With climate change, NDs may spread to US and Europe. Despite the biotech revolution, most new drugs and therapies target cancer and rare diseases, focusing on the developed world, while therapies for NDs remain underdeveloped and underfunded. 

RebelPharma (RP) scouts, identifies, and partners with researchers with molecules on the valley of death targeting NDs, acquires these molecules and runs phase I and II clinical trials and then sells the successful ones to big pharma. 

RebelPharma

Introduction

Problem

Opportunity